Literature DB >> 30869746

HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.

Giacomo Bregni1, Stefania Sciallero1, Alberto Sobrero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30869746     DOI： 10.1001/jamaoncol.2018.7229

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  10 in total

Review 1.  Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies.

Authors:  Christine M Parseghian; Stefania Napolitano; Jonathan M Loree; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2019-07-01       Impact factor: 12.531

Review 2.  The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.

Authors:  Javier Ros; Iosune Baraibar; Giulia Martini; Francesc Salvà; Nadia Saoudi; José Luis Cuadra-Urteaga; Rodrigo Dienstmann; Josep Tabernero; Elena Élez
Journal:  Curr Treat Options Oncol       Date:  2021-11-06

3.  Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis.

Authors:  Jiawei Zhou; Yutong Liu; Yubo Zhang; Quefeng Li; Yanguang Cao
Journal:  Cancer Res       Date:  2019-11-01       Impact factor: 12.701

4.  HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer.

Authors:  Yoshiaki Nakamura; Kentaro Sawada; Satoshi Fujii; Takayuki Yoshino
Journal:  ESMO Open       Date:  2019-07-08

Review 5.  Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.

Authors:  Naoya Kitamura; Shinya Sento; Yasumasa Yoshizawa; Eri Sasabe; Yasusei Kudo; Tetsuya Yamamoto
Journal:  Int J Mol Sci       Date:  2020-12-29       Impact factor: 5.923

6.  Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer.

Authors:  Li Liang; Mengling Liu; Xun Sun; Yitao Yuan; Ke Peng; Khalid Rashid; Yiyi Yu; Yuehong Cui; Yanjie Chen; Tianshu Liu
Journal:  Cancer Cell Int       Date:  2021-02-25       Impact factor: 5.722

Review 7.  Emerging actionable targets to treat therapy-resistant colorectal cancers.

Authors:  Emanuela Grassilli; Maria Grazia Cerrito
Journal:  Cancer Drug Resist       Date:  2022-01-04

8.  CAF-derived exosomal WEE2-AS1 facilitates colorectal cancer progression via promoting degradation of MOB1A to inhibit the Hippo pathway.

Authors:  Peng Yang; Dongsheng Zhang; Tuo Wang; Jiangzhou Ji; Chi Jin; Chaofan Peng; Yuqian Tan; Jiahui Zhou; Lu Wang; Yifei Feng; Yueming Sun
Journal:  Cell Death Dis       Date:  2022-09-19       Impact factor: 9.685

Review 9.  New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer.

Authors:  Angela Damato; Martina Rotolo; Francesco Caputo; Eleonora Borghi; Francesco Iachetta; Carmine Pinto
Journal:  Life (Basel)       Date:  2022-07-28

10.  Towards the era of precision medicine in metastatic colorectal cancer.

Authors:  Stefania Napolitano; Teresa Troiani; Erika Martinelli; Fortunato Ciardiello
Journal:  ESMO Open       Date:  2020-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.